| Methods |
Randomised clinical trial. |
| Participants |
Country: Belgium.
Sample size: 19.
Post‐randomisation drop‐out(s): not stated.
Revised sample size: 19.
Females: not stated.
Mean age: not stated.
Piggyback: not stated.
Conventional: not stated.
Cadaveric donor: not stated.
Live donor: not stated.
Inclusion criteria:
1. Patients undergoing orthotopic liver transplantation. |
| Interventions |
The patients were randomised to the following groups.
Group 1: intervention (n = 10).
Further details: aprotinin 187,500 KIU/hour from the beginning of the procedure.
Group 2: control (n = 9).
Further details: control (placebo). |
| Outcomes |
The outcomes reported were blood loss and blood transfusion requirements. |
| Notes |
Attempts were made to contact the author in September 2011. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Comment: This information was not available. |
| Allocation concealment (selection bias) |
Unclear risk |
Comment: This information was not available. |
| Blinding of participants and personnel (performance bias)
All outcomes |
Unclear risk |
Comment: A placebo was used. It was not clear what was used for placebo. |
| Blinding of outcome assessment (detection bias)
All outcomes |
Unclear risk |
Comment: A placebo was used. It was not clear what was used for placebo. |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Comment: This information was not available. |
| Selective reporting (reporting bias) |
High risk |
Comment: Important outcomes were not reported. |
| Vested interest bias |
Unclear risk |
Comment: This information was not available. |
